NASDAQ$DSGN
Design Therapeutics Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Design Therapeutics reported Q4 2023 financial results and outlined progress across its GeneTAC™ platform.
Design Therapeutics reported a net loss of $11.8 million for the fourth quarter of 2023. The company's cash and securities totaled $281.8 million at year-end, supporting a five-year operating runway. Progress was highlighted across the GeneTAC™ platform, including a new drug product for Friedreich Ataxia and IND clearance for Fuchs Endothelial Corneal Dystrophy.
- New drug product DT-216P2 for Friedreich Ataxia (FA) shows favorable nonclinical pharmacokinetic and injection site safety profile.
- IND cleared for DT-168 for treatment of Fuchs Endothelial Corneal Dystrophy (FECD), with Phase 1 development to start in 2024.
- New program unveiled for Huntington’s Disease (HD) targeting reduction of mutant huntingtin with a GeneTAC™ small molecule.
- Cash and securities of $281.8 million at year-end 2023 support a five-year operating runway and advancement of up to four programs to clinical proof-of-concept.
Headline financials
Revenue & EPS history
Design Therapeutics · Revenue · Quarterly
$838K
Forward guidance
Design Therapeutics expects cash to fund operating expenses through the next five years.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2023
-2.2%
Avg return
Earnings day
+1.7%
Avg return
5 days after
+3.2%
Avg return
30 days after
50%
10 / 20 earnings
Positive
+15.1%
Q4 2023
Best reaction
-71.7%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | +3.8% | -16.2% | |
| Q4 2025 | +3.2% | +0.7% | +26.1% | |
| Q3 2025 | +10.7% | +10.8% | +42.2% | |
| Q2 2025 | -8.9% | +14.5% | +48.3% | |
| Q1 2025 | +0.3% | +10.3% | +10.3% | |
| Q4 2024 | +0.4% | +2.5% | -27.2% | |
| Q3 2024 | -1.9% | +16.3% | +7.9% | |
| Q1 2024 | +1.7% | -3.0% | -17.9% | |
| Q4 2023 | +15.1% | +50.8% | +48.4% | |
| Q3 2023 | +13.9% | +10.4% | +27.4% | |
| Q2 2023 | -71.7% | -72.8% | -65.2% | |
| Q1 2023 | -12.2% | -12.6% | -26.4% | |
| Q4 2022 | -0.6% | -8.1% | -24.8% | |
| Q3 2022 | -0.3% | -0.8% | -9.7% | |
| Q2 2022 | +0.3% | +13.5% | +5.5% | |
| Q1 2022 | -1.5% | -2.4% | +30.9% | |
| Q4 2021 | -1.8% | -0.8% | -10.0% | |
| Q3 2021 | +4.8% | +10.7% | -3.8% | |
| Q2 2021 | +9.9% | +7.9% | +19.7% | |
| Q1 2021 | -6.0% | -18.0% | -1.8% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro